Matthew Angel
Known title: CEO and PresidentCIK: 0001931356
Matthew Angel's purchase track record
Matthew Angel has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/24/2026 | TPST | $1.00M | -28.3% | -42.9% | +18.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TPST | ▲ Buy | Open Market | 231,482 | $500K | 3/24/2026 | View on chart |
| TPST | ▲ Buy | Open Market | 231,482 | $500K | 3/24/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
TPST Files Prospectus to Register Resale of Up to 9.5M Shares
Tempest Therapeutics has filed a prospectus to register the resale of up to 9,534,164 shares of common stock. This filing allows the company to offer more shares to the public, potentially increasing the available supply. The move is a routine corporate action that may influence the stock’s liquidity and market perception.
TPST Files Prospectus to Register Resale of Up to 9.5M Shares. Tempest Therapeutics has filed a prospectus to register the resale of up to 9,534,164 shares of common stock. This filing allows the company to offer more shares to the public, potentially increasing the available supply. The move is a routine corporate action that may influence the stock’s liquidity and market perception.